



Canadian Society  
of Surgical Oncology  
(CSSO)



(CaGCA)



# Multidisciplinary Considerations for Treatment of Gastric Cancer

University of Toronto Faculty Club, Toronto, Ontario, June 9-10, 2022

Dear Participants,

The CaGCA and CSSO welcome you to the Bi-Annual Canadian Gastric Cancer Conference. As you all know, gastric cancer is quite rare in Canada and many efforts and new research is continuously evolving to improve care and cancer outcomes for gastric cancer patients. This program is designed to provide a comprehensive update in the Multidisciplinary approach to Gastric Cancer management. We have a roster of excellent International and National Speakers to share their insights and present the most up to date data on gastric cancer in their relative fields from GI, Pathology, Surgery and Medical/Radiation Oncology. This 2-day event will be filled with lectures, panel discussions, interactive questions and “How I do it” videos. We also have the privilege of having our patients join us via My Gut Feeling, a gastric cancer patient advocacy group, to share their perspectives with us. We are happy that you are joining us and we wish you a great meeting!

Your Program Chairs,



Carolyn Nessim, MD, MSc, FRCSC, FACS and Natalie Coburn, MD, MPH, FRCSC, FACS

## Program Committee:

Shaqil Kassam, Medical Oncologist  
Farhana Shariff, Surgical Oncologist  
Alex Mathieson, Surgical Oncologist

Adam Meneghetti, MIS/Upper GI  
Monica Yuen, BSc, Program Assistance  
Victoria Delibasic, Research Coordinator

## KEYNOTE SPEAKERS

### Dr. Yelena Y. Janjigian, Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York City, NY, USA



Yelena Y. Janjigian MD, is Associate Professor and Chief of Gastrointestinal (GI) Oncology Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Her research career and clinical practice are focused on improving treatment outcomes for patients with GI malignancies. She is an international expert in the management of cancers of esophagus and stomach and lead several seminal studies that changed practice and set the standard of care for these diseases. She produced high impact publications describing the genomic basis for esophagogastric cancer pathogenesis and secure federal grants to fund future studies. Her research is focused on developing new treatments, with a special emphasis on defining the therapeutically relevant molecular characteristics of tumors in the GI tract, with 120 peer-reviewed publications to date. Dr. Janjigian received her BS from the University of California, San Diego, and her MD from the New York University School of Medicine. She did her internal medicine residency at New York School of Medicine/Bellevue Hospital and her hematology/oncology fellowship training at MSKCC. She joined the MSK faculty in 2009 as a member of the GI Oncology Service. Dr. Janjigian is an active member of American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR) and European Society for Medical Oncology (ESMO) holding an array of leadership positions. As Chief of the GI Oncology Service, Dr. Janjigian's mission is to foster research and innovation that transform the future of GI oncology to help patients worldwide.

### Mr. Bilal Alkhaffaf, MIS Surgeon, Salford Royal NHS Foundation Trust, Manchester, UK



Mr. Alkhaffaf qualified from the University of Manchester in 2003 and completed his surgical training in the Northwest of England. He has a specialist interest in minimally invasive (keyhole) surgery and has expanded his experience in this field by visiting international centres of excellence in the United States, South Korea, and The Netherlands. Since the reorganisation of esophago-gastric cancer services in Greater Manchester in 2018, Mr. Alkhaffaf is based at Salford Royal NHS Foundation Trust, however, holds a weekly outpatient's clinic at Wythenshawe hospital.

In 2013 Mr. Alkhaffaf was awarded a 'National Institute for Health Research Doctoral Research Fellowship', funding a 5-year international study to standardise the reporting of outcomes in future gastric cancer surgery trials

### Dr. Yang Hee Woo, Surgical Oncologist, City of Hope, Duarte, California, USA



Yanghee Woo, M.D., is an internationally recognized surgeon scientist with expertise in robotic surgery and gastric cancer. As a leader in her field, Dr. Woo has dedicated her unique perspective, training, and expertise to bring the best of surgical innovation and medical discoveries to transform cancer care of her patients and cancer patients worldwide. Dr. Woo has been awarded the "Illuminator Award" by Hope for Stomach Cancer for her visionary work in stomach cancer and the "Community Leader in Medicine Award" by the Korean American Federation of LA for her efforts to eliminate disparities in cancer care in our communities.

Dr. Woo's education, training and experiences have equipped her well as an exemplary cancer surgeon. She graduated from Princeton University with a B.A. in political science, received her M.D. from Drexel University Medical School, completed the general surgery residency at Columbia University Medical Center (CUMC), the research fellowship at Memorial Sloan Kettering Cancer Center (mentored by Yuman Fong, M.D., the Sangiacomo Family Chair in Surgical Oncology) and a clinical fellowship at Severance Hospital, Yonsei University, Seoul (mentored by Woo Jin Hyung, M.D., Ph.D.).

Dr. Woo is an unstoppable force spearheading our transformative programs in robotic cancer surgery and gastric cancer at City of Hope. She is an associate professor of surgery, director of international surgery and director of the Gastroenterology Minimally Invasive Therapy Program in the Division of Surgical Oncology, Department of Surgery. In collaboration with her national and international colleagues, her multidisciplinary team of clinicians, scientists, immunologists, bioinformaticians at City of Hope investigates immune biomarkers for earlier detection of gastrointestinal cancers, translates novel targeted agents, such as oncolytic viruses, into effective diagnostic and therapeutic tools for cancer patients, and safely integrates advancements in surgical technologies to improve patient outcomes. Funded by the Department of Defense Idea Award, AACR's first SU2C Stomach Cancer Interception Award, the Ohr Foundation, and other generous donations to City of Hope, her ongoing contributions to the field are reflected in the growing number of publications in peer-reviewed manuscripts, authored textbook chapters and invited lectures.

# Accommodations

Dear Participants,

Thank you so much for expressing your interest in attending the upcoming Annual Canadian Gastric Cancer Conference hosted by CaGCA and CSSO. This year, we are delighted to have our two-day conference held at the University of Toronto Faculty Club, 41 Willcocks St, Toronto, ON M5S 3G3, from Thursday June 9<sup>th</sup> to Friday June 10<sup>th</sup>.

Please see below a list of some hotels located nearby the conference venue to help you book your stay.

We look forward to this great meeting and your attendance!

## **Kimpton Saint George Hotel**

1 km from the University of Toronto – Faculty Club  
280 Bloor St W, Toronto, ON M5S 1V8 Canada  
<https://www.kimptonsaintgeorge.com/>

## **The Yorkville Royal Sonesta Hotel**

1.3 km from the University of Toronto – Faculty Club  
220 Bloor Street West, Toronto, ON M5S 1T8  
<https://www.sonesta.com/royal-sonesta/on/toronto/yorkville-royal-sonesta-hotel-toronto/>

## **Chelsea Hotel**

1.9 km from the University of Toronto – Faculty Club  
33 Gerrard Street West, Toronto, Ontario M5G 1Z4 Canada  
<https://www.chelseatoronto.com/en/>

## **Double Tree by Hilton Toronto**

1.9 km from the University of Toronto – Faculty Club  
108 Chestnut Street, Toronto, Ontario, M5G1R3, Canada  
<https://www.hilton.com/en/hotels/ytocsd-t-doubletree-toronto-downtown/>

## **Marriott Downtown at CF Toronto Eaton Centre**

2.2 km from the University of Toronto – Faculty Club  
525 Bay St., Toronto, ON M5G 2L2  
<https://www.marriott.com/en-us/hotels/yyzec-marriott-downtown-at-cf-toronto-eaton-centre/overview/>

## **ACCREDITATION (CME Credits)**

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by Canadian Association of General Surgeons. You may claim a maximum of 14 hours.

# Overall Meeting Objectives:

By the end of this 2-day meeting the participants will be able to:

- Discuss the newest approaches to diagnosis and pathology in the management of Gastric Cancer
- Discuss measures for quality improvement in Gastric Cancer
- Discuss the management of patients with CDH1 mutations
- Describe the different surgical approaches to Gastric Cancer and the controversies involved in Gastric Cancer Surgery
- Describe the findings of the latest clinical trials with regards to Systemic Treatment of Gastric Cancer
- Describe the findings of the latest clinical trials with regards to Radiation Therapy of Gastric Cancer

## Thursday June 9, 2022

### **8:00-8:30am: Welcome Reception Breakfast and Sign-in**

8:30-8:35am: **Welcoming remarks** (Dr. Carolyn Nessim and Dr. Natalie Coburn)

8:35-8:45am: **Welcoming remarks from “My Gut Feeling”** (Teresa Tiano and Katy Kosyachkova, (Gastric Cancer Survivors and Co-Founders of My Gut Feeling)

### **QUALITY INDICATORS AND OUTCOMES**

8:45-9:10am: **Quality Indicators, Reported Outcomes and Disparities in Gastric Cancer** – Dr. Carol Swallow (Surgical Oncologist, Mount Sinai Hospital, Toronto, Ontario)

Objectives: By the end of this talk the learner will be able to:

- Describe the Quality Indicators in Gastric Cancer
- Describe how to apply these quality indicators in their practice
- Discuss the disparities that exist in access to care in Canada

9:10-9:30am: - **The development of a Pan-Canadian Gastric Cancer Database** – Dr. Daniel Schiller (Surgical Oncologist, University of Alberta, Edmonton, Alberta)

Objectives: By the end of this talk the learner will be able to:

- Describe the importance of multi-institutional real-world data for rare cancers
- Describe how to participate in a national database – the pros and the challenges

## DIAGNOSTICS

9:30-10:00am: **GI Diagnostics – The role of EUS and ESD in Gastric Cancer** - Dr. Natalia Calo (Gastroenterologist, The Ottawa Hospital, Ottawa, Ontario)

Objectives: By the end of this talk the learner will be able to:

- List the indications for EUS in Gastric Cancer and explain its utility
- Describe the Indications and Criteria for ESD in Early-Stage Gastric Cancer

10:00-10:30am: **Pathology – The utility of Reflex testing of Her-2 and MSI in Gastric Cancer** - Dr. Aaron Pollett (Pathologist, Mount Sinai Hospital, Toronto, Ontario)

Objectives: By the end of this talk the learner will be able to:

- Describe the benefits of Reflex Testing for Her-2 and MSI in Gastric Cancer
- Describe how the results of Her-2 and MSI testing can inform systemic treatment

10:30-10:45am: **PANEL - Q&A**

## 10:45-11:05 BREAK

11:05-11:55pm: **Diagnostic Laparoscopy – How do you do it? Is there a Standard? Pan-Canadian Live Audience Survey** – Dr. Carolyn Nessim (Surgical Oncologist, The Ottawa Hospital, Ottawa, Ontario)

Objectives: By the end of this talk the learner will be able to:

- Describe the indications for Dx Laparoscopy in Gastric Cancer
- Describe the ideal timing in the patients' journey for Diagnostic Laparoscopy
- Describe the significance of a positive cytology and how this affects decision making

## 12:00-1:00pm – Sponsored Lunch Symposium – Unaccredited Activity

## GENETICS / PALLIATION

1:00-1:30pm: **My patient was just diagnosed with a CDH1 mutation, now what?** – Dr. Alex Mathieson (Surgical Oncologist, Memorial University, St-John's, Newfoundland)

Objectives: By the end of this talk the learner will be able to:

- Describe the geographical distribution of patients affected with CDH1
- Describe the Endoscopy frequency and biopsy pattern for patients with CDH1
- Describe the optimal timepoint for prophylactic surgery for patients with CDH1
- Describe the other cancers associated with CDH1 mutation



1:30-2:00pm: **Hereditary Gastric Cancer Syndromes** – Melyssa Aaronson (Genetic Counsellor -Zane Cohen Centre/Sinai Health System)

Objectives: By the end of this talk the learner will be able to:

- Describe the indications for genetic testing in patients diagnosed with Gastric Cancer
- Describe the common hereditary conditions associated with hereditary gastric cancer
- Describe the outcome of genetic testing on a cohort of Ontario Gastric cancer patients

2:00-2:30pm: **The Role of Palliative Surgery in Gastric Cancer** –(Dr. Trevor Hamilton, Vancouver General Hospital, UBC, Vancouver, BC)

Objectives: By the end of this talk the learner will be able to:

- Identify patients that may be considered for palliative surgery for symptomatic gastric cancer
- Discuss the presentation of symptomatic gastric cancer patients with locally advanced disease

2:30-3:00pm: **Patient Advocacy – The development of a patient advocacy group** – Teresa Tiano and Katy Kosyachkova, (Gastric Cancer Survivors and Co-Founders of My Gut Feeling)

Objectives: By the end of this talk the learner will be able to:

- Describe the patient's experience with gastric cancer
- Describe how clinicians can get involved in patient advocacy groups for more collaboration

3:00-3:30pm: **PANEL - Q&A**

**3:30-3:50pm - BREAK**

## **SURGERY**

3:50-4:20pm: **The role of Subtotal vs. Total Gastrectomy and D2 Dissection in Gastric Cancer** – Dr. Farhana Shariff (Surgical Oncologist, University of Manitoba, Winnipeg, Manitoba)

Objectives: By the end of this talk the learner will be able to:

- Describe the ideal margins of resection for gastric cancer
- Describe the role and importance of D2 Dissection
- Discuss the role of Extended D3 Dissection

4:20-4:50pm: **To Pouch or not to Pouch Post-Gastrectomy? A review of the Functional Outcomes** – (Dr. Natalie Coburn – Surgical Oncologist and HPB Surgeon – Sunnybrook Health Sciences Center, Toronto, Ontario)

Objectives: By the end of this talk the learner will be able to:

- Describe Pouch procedures and the functional pros and cons
- Describe the indications of creating a pouch reconstruction
- Describe the technique of pouch reconstruction

4:50-5:05pm: **PANEL – Q&A**

**7:00-9:00pm - Sponsored Dinner Symposium – Unaccredited Session**

## **Friday June 10, 2022**

**8:00-8:30am: Breakfast**

### **SYSTEMIC THERAPY**

8:30-9:10am: **Update on Chemotherapy and Targeted Therapy for Gastric Cancer – KEYNOTE**

**SPEAKER** - Dr. Yelena Y. Janjigian (Medical Oncologist, Memorial Sloan Kettering, New York City, USA)

Objectives: By the end of this talk the learner will be able to:

- Describe the peri-operative chemotherapy treatment for gastric cancer
- Describe the role of Herceptin in Gastric Cancer

9:10-9:40am: **HIPEC for Gastric Cancer** – Dr. Mai-Kim Gervais (Surgical Oncologist, Hôpital Maisonneuve-Rosemont, Montreal, Quebec)

Objectives: By the end of this talk the learner will be able to:

- Describe the outcomes of Clinical Trials thus far for HIPEC in Gastric Cancer
- Describe the potential patients that may benefit from HIPEC

9:40-10:10am: **Update on the Role of Immunotherapy in Gastric Cancer** - Dr. Shaqil Kassam (Medical Oncologist, Southlake Regional Health Center, Newmarket, Ontario)

Objectives: By the end of this talk the learner will be able to:

- Describe the role of immunotherapy in Gastric Cancer
- Describe the indications for immunotherapy in Gastric Cancer

10:10-10:35 - **PANEL – Q&A**

**10:35-10:55 - BREAK**

## GE-JUNCTION GASTRIC CANCER

10:55-11:25am: **GE junction cancers- Laparotomy or Thoracotomy? – KEYNOTE SPEAKER** - Mr. Bilal Alkhaffaf (MIS Surgeon, Manchester Hospital, UK)

Objectives: By the end of this talk the learned will be able to:

- Describe the best surgical approach to GEJ cancers
- Discuss Open vs. Laparoscopic Approach to GEJ cancers

11:25-12:05pm: **Great DEBATE – FLOT vs. CROSS, Which is better? –**  
**For FLOT** (Dr. Elena Elimova, Medical Oncologist, Princess Margaret Hospital)  
**For CROSS** (Dr. Jason Pantarotto, Radiation Oncologist, The Ottawa Hospital, Ottawa, Ontario)

Objectives: By the end of this talk the learned will be able to:

- Describe the Pros and Cons of FLOT Chemotherapy for GEJ cancers
- Discuss the Pros and Cons of CROSS Radio-chemotherapy for GEJ cancers

## 12:05-1:05pm - LUNCH

## SURGERY

1:05-1:35pm: **Patient focused outcomes in gastric cancer – How to improve clinical trial design in the future - KEYNOTE SPEAKER** - Mr. Bilal Alkhaffaf (MIS Surgeon, Manchester Hospital, UK)

Objectives: By the end of this talk the learned will be able to:

- Define patient focused outcomes in gastric cancer
- Discuss the benefit of focusing on patient focused outcomes in future clinical trials

1:35-2:05pm: **Minimally Invasive Approaches to Gastric Cancer and Outcomes – KEYNOTE SPEAKER** - Dr. Yang Hee Woo (Surgical Oncologist, City of Hope, California, USA)

Objectives: By the end of this talk the learner will be able to:

- Describe the outcomes of MIS Gastric Cancer Surgery vs. Open
- Describe how to integrate MIS Surgery into your practice

2:05-2:35pm: **The Influence of GEJ classification on Multimodal Management and Surgical Approach –**  
Dr. Lorenzo Ferri (Thoracic Surgeon, McGill University, Montreal, Quebec)

Objectives: By the end of this talk the learner will be able to:

- Discuss how GEJ classification affects management decisions
- Discuss the multi-management approach to Gastric Cancer
- Describe the surgical approach to gastric cancer based on GEJ Classification



2:35-3:05pm: **Post-operative complications – How are they best managed?** – Dr. Adam Meneghetti (MIS/Upper GI, Vancouver General Hospital, Vancouver, BC)

Objectives: By the end of this talk the learner will be able to:

- Describe the management of an anastomotic leak
- Describe the management of dumping syndrome
- Describe the best post gastrectomy diet
- Describe the management of long-term vitamin deficiencies

3:05-3:35: **PANEL – Q&A**

**3:35-3:55pm - BREAK**

## **RADIATION THERAPY**

3:55-4:25pm: **Update on Radiation Therapy in Gastric Cancer** – Dr. Vimoj Nair (Radiation Oncologist, The Ottawa Hospital, Ottawa, Ontario)

Objectives: By the end of this talk the learner will be able to:

- Describe the indications for radiation in resectable gastric cancer
- Describe the indication for radiation in palliative gastric cancer

## **MULTI-DISCIPLINARITY**

4:25-5:25pm: **Multi-disciplinary tumour board – Case presentations to Expert Panel –**

- Moderator: Dr. Trevor Hamilton (Vancouver General Hospital, UBC)
- Surgeon: Dr. Carol Swallow (Mount Sinai Hospital, Toronto)
- Medical Oncologist: Dr. Elena Elimova (Princess Margaret Hospital, Toronto)
- Radiation Oncologist: Dr. Vimoj Nair (The Ottawa Hospital, Ottawa)
- Pathologist: Dr. Aaron Pollett (Mount Sinai Hospital, Toronto)

Objectives: By the end of this talk the learner will be able to:

- Discuss the Complexities of decision making in gastric cancer care
- Describe the utility of a Multidisciplinary approach to gastric cancer

5:25-5:30pm: **Closing Remarks** (Dr. Carolyn Nessim and Dr. Natalie Coburn)

## **SPONSORED SESSIONS**

### **12:00-1:00pm – Sponsored Lunch Symposium – Astra Zeneca - The Emerging role of Immunotherapy in Gastric Cancer - Panel with Case discussions –**

- Dr. Christine Brezden-Masley (Medical Oncologist, Mount Sinai Hospital, Toronto, Ontario)
- Dr. Carol Swallow (Surgical Oncologist, Mount Sinai Hospital, Toronto, Ontario)
- Dr Shaqil Kassam (Medical Oncologist, Southlake Regional Health Center, Newmarket, Ontario)
- Dr. Carolyn Nessim (Surgical Oncologist, The Ottawa Hospital, Ottawa, Ontario)

### **7:00-9:00pm - Sponsored Dinner Symposium – Bristol Myers Squibb Innovation in Drug Development for the Treatment of Gastric Cancer**

- **KEYNOTE SPEAKER** - Dr. Yelena Y. Janjigian (Medical Oncologist, Memorial Sloan Kettering, New York City, USA)

**LOCATION:** *Sassafras Restaurant*, 100 Cumberland St, Toronto, ON M5R 1A6

Thank you to our Sponsors:

